Protagonist Therapeutics Inc
PTGX
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.96B
Close$
$-3.77
102.7% downside
Current Fair Value
102.7% downsideOvervalued by 102.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.96 Billion |
|---|---|
| Enterprise Value | $8.56 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.05 |
| Beta | 1.79 |
| Outstanding Shares | 65,935,769 |
Return
| Return on Equity | 9.85% |
|---|---|
| Return on Assets | 9.36% |
| Return on Invested Capital | 8.36% |
Valuation & Multiples
| P/E Ratio | 113.64 |
|---|---|
| PEG | -20 |
| Price to Sales | 46.14 |
| Price to Book Ratio | 11.54 |
| Enterprise Value to Revenue | 37 |
| Enterprise Value to EBIT | 120.65 |
| Enterprise Value to Net Income | 103 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$2.23
Average shareholder expectationRevenue Estimate
$198.66 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$2.50
Average shareholder expectationRevenue Estimate
$238.48 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 59.35% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.10%▼ 115.73% |
|---|---|
| Total Invested | $9.71M▼ 99.90% |
| Investors Holding | 25▼ 333.00% |
ESG Score
No data